{"nctId":"NCT00415519","briefTitle":"Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III","startDateStruct":{"date":"2006-12"},"conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"count":25,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: MCI-186"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo of MCI-186"]}],"interventions":[{"name":"MCI-186","otherNames":["Edaravone","Radicut"]},{"name":"Placebo of MCI-186","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who are defined as \"definite ALS,\" \"probable ALS\" or \"probable-laboratory-supported ALS,\" met diagnostic criteria revised EL Escorial for Airlie House.\n* Patients who cannot take at least one action of eating a meal, excreting, or moving with oneself alone, and need assistance in everyday life.\n* Patients whose progress of the condition during 12 weeks before administration meet other requirements.\n\nExclusion Criteria:\n\n* Patients judged to be inadequate to participate in this study by their physician, because those patients' general condition deteriorated to the point that they need to be hospitalized for severe hepatic disease, sever heart disease, sever renal disease and so on, or they need to be administered antibiotics to infection.\n* Patients who complain the difficulty in breathing caused by deteriorating the respiratory function.\n* Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of hypersensitivity to edaravone.\n* Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to contraception.\n* Patients who have been administered other investigational products within 12 weeks before consent, or who are participating in other clinical trials at present.\n* In addition to the above exclusion criteria, patients judged to be inadequate to participate in this study by their physician.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks","description":"No primary endpoint was used, because various exploratory analyses were performed.\n\n0=worst; 48=best","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.52","spread":"1.78"},{"groupId":"OG001","value":"-6","spread":"1.83"}]}]}]},{"type":"PRIMARY","title":"Death or a Specified State of Disease Progression","description":"No primary endpoint was used, because various exploratory analyses were performed.\n\nAny of \"death, disability of independent ambulation, loss of upper arm function, tracheotomy, use of respirator, and use of tube feeding\" was defined as an event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks","description":"No primary endpoint was used, because various exploratory analyses were performed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.75","spread":"4.58"},{"groupId":"OG001","value":"-15.69","spread":"4.58"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Adverse Events","description":"No primary endpoint was used, because various exploratory analyses were performed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Adverse Drug Reactions","description":"No primary endpoint was used, because various exploratory analyses were performed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":null},{"groupId":"OG001","value":"8.3","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentage of Participants With an Abnormal Change in Laboratory Tests That Occurred in More Than Two Patients","description":"No primary endpoint was used, because various exploratory analyses were performed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":null},{"groupId":"OG001","value":"8.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Abnormal Changes in Sensory Examinations","description":"No primary endpoint was used, because various exploratory analyses were performed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":13},"commonTop":["Headache","Diarrhoea","Gait disturbance","Nasopharyngitis","Upper respiratory tract inflammation"]}}}